Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory ...

Merck & Co., Inc. (NYSE:MRK) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Cantor Fitzgerald reaffirmed its Neutral rating on Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...

Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ...

Find the latest Merck & Co., Inc. (MRK) stock quote, history, news and other vital information to help you with your stock trading and investing.

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.

Merck & Co Inc. Follow. 844 results. June 27, 2025. Gilead shares rise after US top court ruling on preventive coverage. Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a ...

Merck & Co's earlier efforts to find new therapies for Alzheimer's disease resulted in failure, but the company is returning to the field via an R&D alliance with UK biotech Cerevance that will ...

Merck now has one cardiovascular candidate left in phase 3: vericiguat, an oral soluble guanylate-cyclase (sGC) stimulator being studied as a new heart failure treatment. Image Richard Staines ...

In other recent news, Merck & Co. Inc. has reported successful Phase 3 trial results for its cholesterol drug, enlicitide decanoate, which showed significant reductions in LDL cholesterol levels. The ...